Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK

PloS One
Lara J WolfsonGerhart Knerer

Abstract

To evaluate the cost-effectiveness of adding bedaquiline to a background regimen (BR) of drugs for multidrug-resistant tuberculosis (MDR-TB) in the United Kingdom (UK). A cohort-based Markov model was developed to estimate the incremental cost-effectiveness ratio of bedaquiline plus BR (BBR) versus BR alone (BR) in the treatment of MDR-TB, over a 10-year time horizon. A National Health Service (NHS) and personal social services perspective was considered. Cost-effectiveness was evaluated in terms of Quality-Adjusted Life Years (QALYs) and Disability-Adjusted Life Years (DALYs). Data were sourced from a phase II, placebo-controlled trial, NHS reference costs, and the literature; the US list price of bedaquiline was used and converted to pounds (£18,800). Costs and effectiveness were discounted at a rate of 3.5% per annum. Probabilistic and deterministic sensitivity analysis was conducted. The total discounted cost per patient (pp) on BBR was £106,487, compared with £117,922 for BR. The total discounted QALYs pp were 5.16 for BBR and 4.01 for BR. The addition of bedaquiline to a BR resulted in a cost-saving of £11,434 and an additional 1.14 QALYs pp over a 10-year period, and is therefore considered to be the dominant (less costl...Continue Reading

References

Oct 22, 2002·Mathematical Biosciences·Brian M MurphyDenise Kirschner
Jul 24, 2004·BMJ : British Medical Journal·Michael D Rawlins, Anthony J Culyer
Jun 27, 2006·PLoS Medicine·Stephen C ReschMilton C Weinstein
Jan 20, 2007·International Journal of Technology Assessment in Health Care·Michael F DrummondJoan Rovira
May 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Molly F FrankeCarole D Mitnick
Feb 20, 2009·Health and Quality of Life Outcomes·Na GuoCarlo A Marra
Mar 10, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Karl Broich, UNKNOWN Committee for Medicinal Products for Human Use
Aug 27, 2009·Proceedings of the National Academy of Sciences of the United States of America·Fabio LucianiMark M Tanaka
May 6, 2010·American Journal of Respiratory and Critical Care Medicine·Armand Van DeunHans L Rieder
Dec 3, 2010·Bulletin of the World Health Organization·Joshua A Salomon
Sep 29, 2011·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·L GrandjeanD A J Moore
Nov 10, 2011·BMJ : British Medical Journal·Mark JitUNKNOWN Find and Treat Evaluation Team
Jan 4, 2012·Risk Analysis : an Official Publication of the Society for Risk Analysis·Chung-Min LiaoMin-Pei Ling
Jan 31, 2012·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·N SinglaD Behera
Aug 7, 2012·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·J T DenholmE S McBryde
Sep 20, 2012·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Uwe SiebertKaren M Kuntz
Sep 25, 2012·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Uwe SiebertUNKNOWN ISPOR-SMDM Modeling Good Research Practices Task Force
Aug 21, 2013·The European Respiratory Journal·Roland DielAlbert Nienhaus
Jan 7, 2014·Bulletin of the World Health Organization·Grania BrigdenManica Balasegaram
Jun 6, 2014·South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde·F ConradieN Ndjeka
Aug 21, 2014·The New England Journal of Medicine·Andreas H DiaconUNKNOWN TMC207-C208 Study Group
Oct 17, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lorenzo GuglielmettiUNKNOWN MDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Coh
Jul 15, 2015·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·N NdjekaY Pillay

❮ Previous
Next ❯

Citations

Feb 18, 2016·Transactions of the Royal Society of Tropical Medicine and Hygiene·Derek J Sloan, Joseph M Lewis
Sep 22, 2015·International Journal of Pediatric Otorhinolaryngology·Peter S HanJared C Inman
Jun 21, 2016·Expert Review of Clinical Pharmacology·T V A NguyenJ W C Alffenaar
Jun 9, 2016·Expert Review of Respiratory Medicine·Alberto MatteelliGiovanni Battista Migliori
Mar 8, 2017·Journal of Market Access & Health Policy·Luigi R CodecasaSaverio De Lorenzo
Jun 28, 2017·Journal of Chemotherapy·Lucie BarthodPatrice Vanelle
Jun 20, 2018·Respirology : Official Journal of the Asian Pacific Society of Respirology·Kwok-Chiu ChangChi-Chiu Leung
Oct 24, 2015·The European Respiratory Journal·Lara J WolfsonRoland Diel
Jun 30, 2019·Medicinal Research Reviews·Aparna Bahuguna, Diwan S Rawat
Apr 29, 2020·International Journal of Technology Assessment in Health Care·Xue FengDaniel A Ollendorf

❮ Previous
Next ❯

Software Mentioned

Winbugs

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.